Skip to main content

Advertisement

SpringerLink
Log in

Thymalfasin

Clinical Pharmacology and Antiviral Applications

  • Immunology-Based Agents
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

Thymalfasin (thymosin-α1) is an immunomodulatory agent that is able to augment some specific T lymphocyte functions, particularly that of promoting the T helper 1 cell responses involved in host antiviral defence. The most promising clinical applications for thymalfasin seem to be as a single agent for the treatment of chronic hepatitis B and in combination with interferon-α for the treatment of both chronic hepatitis B and C. These positive preliminary results offer a strong rationale for larger, well-planned clinical trials and also for defining the optimal schedule of administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goldstein AL, White A. The thymus gland: experimental and clinical studies of its role in the development and expression of immune functions. In: James VMT, Martini L, editors. Current topics in experimental endocrinology. New York: Academic Press, 1971: 121–49

    Google Scholar 

  2. Miller JFAP. Immunological function of the thymus. Lancet 1961; II: 748–9

    Article  Google Scholar 

  3. Archer OK, Pierce JC. Role of thymus in development of the immune response. Fed Proc 1961; 20: 26

    Google Scholar 

  4. De George AM. Congenital absence of the thymus and its immunologic consequences: concurrence with congenital hypoparathyroidism. Birth Defects 1968; 4: 116–23

    Google Scholar 

  5. Goldstein AL, Slater FD, White A. Preparation, assay and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA 1966; 56: 1010–7

    Article  PubMed  CAS  Google Scholar 

  6. Low TLK, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. I. Isolation, characterization and biological activities of thymosin α1 and polypeptide β1 from calf thymus. J Biol Chem 1979; 254: 981–6

    PubMed  CAS  Google Scholar 

  7. Haritos AA, Goodall GJ, Horecker BL. Prothymosin alpha: isolation and properties of major immunoreactive form of thymosin alpha-1 in rat thymus. Proc Natl Acad Sci USA 1984; 81: 1008–11

    Article  PubMed  CAS  Google Scholar 

  8. Eschenfeldt WH, Berger SL. The human prothymosin alpha gene is polymorphic and induces growth stimulation: evidence using a cloned cDNA. Proc Natl Acad Sci USA 1986; 83: 9403–7

    Article  PubMed  CAS  Google Scholar 

  9. Goodall GJ, Dominguez F, Horecker BL. Molecular cloning of cDNA for human prothymosin α. Proc Natl Acad Sci USA 1986; 83: 8926–8

    Article  PubMed  CAS  Google Scholar 

  10. Eschenfeldt WH, Manrow RE, Krug MS, et al. Isolation and partial sequencing of the human prothymosin alpha gene family: evidence against export of the gene products. J Biol Chem 1989; 264: 7546–55

    PubMed  CAS  Google Scholar 

  11. Haritos AA, Tsolas O, Horecker BL. Distribution of prothymosin alpha in rat tissues. Proc Natl Acad Sci USA 1984; 81: 1391–3

    Article  PubMed  CAS  Google Scholar 

  12. Gomez-Marquez J, Segade F, Dosil M, et al. The expression of prothymosin alpha gene in T lymphocytes and leukemic lymphoid cells is tied to lymphocyte proliferation. J Biol Chem 1989; 264: 8451–5

    PubMed  CAS  Google Scholar 

  13. Gomez-Marquez J, Segade F. Prothymosin a is a nuclear protein. FEBS Lett 1988; 226: 217–9

    Article  PubMed  CAS  Google Scholar 

  14. Manrow RE, Sburlati AR, Hanover JA, et al. Nuclear targeting of prothymosin alpha. J Biol Chem 1991; 26: 3916–24

    Google Scholar 

  15. Szabo P, Weksler ME. Is thymosin α1 a thymic hormone? Clin Immunol Immunopathol 1992; 65: 195–200

    Article  PubMed  CAS  Google Scholar 

  16. Franco FJ, Diaz C, Barcia M, et al. Thymosin α1 is a native peptide in several tissues. Biochim Biophys Acta 1992; 1120: 43–8

    Article  PubMed  CAS  Google Scholar 

  17. Wang SS, Makofske R, Bach AE, et al. Solid phase synthesis of thymosin α1. Int J Pept Protein Res 1980; 15: 1–4

    Article  PubMed  CAS  Google Scholar 

  18. Wetzel R, Heyneker HL, Goeddel DV, et al. Production of biologically active Nα-desacetylthymosin α1 in Escherichia coli through expression of a chemically synthesized gene. Biochemistry 1980; 19: 6096–104

    Article  PubMed  CAS  Google Scholar 

  19. Mutchnick MG, Prieto JA, Schaffner JA, et al. Thymosin modulation of regulatory T cell function. Clin Immunol Immunopathol 1982; 23: 626–33

    Article  PubMed  CAS  Google Scholar 

  20. Zatz MM, Oliver J, Samuels C, et al. Thymosin increases production of T-cell growth factor by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1984; 81: 2882–5

    Article  PubMed  CAS  Google Scholar 

  21. Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA 1986; 83: 6107–11

    Article  PubMed  CAS  Google Scholar 

  22. Serrate SA, Schulof RS, Leonaridis L, et al. Modulation of human natural killer cell cytotoxic activity, lymphokine production and interleukin 2 receptor expression by thymic hormones. J Immunol 1987; 139: 2338–43

    PubMed  CAS  Google Scholar 

  23. Baxevanis CN, Reclos GJ, Perez S, et al. Immunoregulatory effects of fraction 5 thymus peptides: thymosin alpha 1 enhances while thymosin beta 4 suppresses the human autologous and allogeneic mixed lymphocyte reaction. Immunopharmacology 1987; 13: 133–41

    Article  PubMed  CAS  Google Scholar 

  24. Thurman GB, Low TLK, Rossio JL, et al. Specific and non-specific macrophage migration inhibition. In: Goldstein AL, Chirigos MA, editors. Lymphokines and thymic hormones: their potential utilization in cancer therapeutics. New York: Raven Press, 1981: 145–57

    Google Scholar 

  25. Huang KY, Kind PD, Jagoda EM, et al. Thymosin treatment modulates production of interferon. J Interferon Res 1981; 1: 411–20

    Article  PubMed  CAS  Google Scholar 

  26. Svedersky LP, Hui A, May L, et al. Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by Nα -desacetylthymosin α1. Eur J Immunol 1982; 12: 244–7

    Article  PubMed  CAS  Google Scholar 

  27. Hsia J, Sarin N, Oliver JH, et al. Aspirin and thymosin increase interleukin-2 and interferon-γ production by human peripheral blood lymphocytes. Immunopharmacology 1989; 17: 167–73

    Article  PubMed  CAS  Google Scholar 

  28. Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol 1989; 7: 789–800

    Article  Google Scholar 

  29. Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol 1990; 12: 19–29

    Article  PubMed  CAS  Google Scholar 

  30. Ahmed A, Wong DM, Thurman GB, et al. T lymphocyte maturation: cell surface markers and immune function induced by T lymphocyte cell free products and thymosin polypeptides. Ann NY Acad Sci 1979; 332: 81–94

    Article  PubMed  CAS  Google Scholar 

  31. Sztein MB, Goldstein AL. Thymic hormones — a clinical update. Springer Semin Immunopathol 1986: 9: 1–18

    Article  PubMed  CAS  Google Scholar 

  32. Schulof RS, Naylor PH, Sztein MB, et al. Thymic physiology and biochemistry. Adv Clin Chem 1987; 26: 203–92

    Article  PubMed  CAS  Google Scholar 

  33. Frasca D, Adorini L, Doria G. Enhanced frequency of mitogen-responsive T cell precursors in old mice injected with thymosin alpha 1. Eur J Immunol 1987; 17: 727–30

    Article  PubMed  CAS  Google Scholar 

  34. Effrros RB, Casillas A, Walford RL. The effect of thymosin alpha 1 on immunity to influenza in aged mice. Aging: Immun Infect Dis 1988; 1: 31–40

    Google Scholar 

  35. Naylor PH, Goldstein AL. Thymosin: cyclic nucleotides and T-cell differentiation. Life Sci 1979; 25: 301–9

    Article  PubMed  CAS  Google Scholar 

  36. Naylor PH, Sheppard H, Thurman GB, et al. Increase of cyclic GMP induced in murine lymphocytes by thymosin fraction five. Biochem Biophys Res Commun 1976; 73: 843–9

    Article  PubMed  CAS  Google Scholar 

  37. Naylor PH, Thurman GB, Goldstein AL. Effect of calcium on the cyclic GMP elevation induced by thymosin fraction five. Biochem Biophys Res Commun 1979; 90: 810–8

    Article  PubMed  CAS  Google Scholar 

  38. Rinaldi-Garaci C, Favalli C, Del Gobbo V, et al. Is thymosin action mediated by prostaglandin release?. Science 1983; 220: 1163–5

    Article  PubMed  CAS  Google Scholar 

  39. Colarian J, Sethi A, Merchant A, et al. Thymosin α1 enhancement of human lymphocyte proliferation is not mediated by prostaglandin E2. Thymus 1990; 15: 241–7

    PubMed  CAS  Google Scholar 

  40. Rinaldi Garaci C, Torrisi MR, Jezzi T, et al. Receptors for thymosin alpha 1 on mouse thymocytes. Cell Immunol 1985; 91: 289–93

    Article  Google Scholar 

  41. Cordero OJ, Sarandeses C, Nogueira M. Prothymosin-α receptors on peripheral blood mononuclear cells. FEBS Lett 1994; 341: 23–7

    Google Scholar 

  42. Oates KK, Naylor PH, Goldstein AL. Localization of thymosin alpha 1 production to thymus medullary epithelial cells by use of monoclonal antibodies. Hybridoma 1987; 6: 47–59

    Article  PubMed  CAS  Google Scholar 

  43. Su YL, Ho KL, Dalkas MC, et al. Localization of immunoreactive thymosin alpha 1 in astrocytes of normal human brain. Ann Neurol 1989; 26: 277–80

    Article  PubMed  CAS  Google Scholar 

  44. Naylor PH, Friedman-Kien A, Hersh AF, et al. Thymosin alpha 1 and thymosin beta 4 in serum: comparison of normal, cord, homosexual and AIDS serum. Int J Immunopharmacol 1986; 8: 667–76

    Article  PubMed  CAS  Google Scholar 

  45. Weller FE, Shah U, Cummings GD, et al. Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults. Thymus 1992; 19: 45–52

    PubMed  CAS  Google Scholar 

  46. Hirokawa K, McClure JE, Goldstein AL. Age-related changes in localization of thymosin in human thymus. Thymus 1982; 4: 19–29

    PubMed  CAS  Google Scholar 

  47. McClure JE, Lameris N, Wara DW, et al. Immunochemical studies on thymosin: radioimmunoassay of thymosin alpha-1. J Immunol 1982; 128: 368–75

    PubMed  CAS  Google Scholar 

  48. McGillis JP, Hall NR, Goldstein AL. Circadian rhythm of thymosin α1 in normal and thymectomized mice. J Immunol 1983; 131: 148–51

    PubMed  CAS  Google Scholar 

  49. Bershof JF, Goldstein AL. Evidence for a circadian rhythm of thymosin alpha-1 in humans. Clin Res 1983; 31: 44

    Google Scholar 

  50. Oates KK, Erdos M. Biochemical identification of thymosin alpha-1: its phylogenetic distribution and evolutionary implications. Comp Biochem Physiol B 1989; 94: 759–63

    Article  PubMed  CAS  Google Scholar 

  51. Low TLK, McClure JE, Naylor PH, et al. Isolation of thymosin α1 from thymosin fraction 5 of different species by high-performance liquid chromatography. J Chromatogr 1983; 266: 533–44

    Article  PubMed  CAS  Google Scholar 

  52. Low TLK, Goldstein AL. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha one and polypeptide beta. J Biol Chem 1979; 254: 987–95

    PubMed  CAS  Google Scholar 

  53. Oates KK, Coss MC. The role of thymosins as biological response modifiers. Med Sci Res 1989; 17: 793–6

    CAS  Google Scholar 

  54. Fidler IJ, Berendt M, Oldham RK. The rationale for design of a screening procedure for the assessment of biological response modifiers for cancer treatment. J Biol Response Mod 1982; 1: 15–26

    Google Scholar 

  55. Oldham RK. Biological response modifiers program. J Biol Response Mod 1982; 1: 81–100

    Google Scholar 

  56. Dillman RO, Beauregard J, Mendelsohn J, et al. Phase I trials of thymosin fraction 5 and thymosin alpha 1. J Biol Response Mod 1982; 1: 35–41

    Google Scholar 

  57. Dillman RO, Beauregard J, Zavanelli MI, et al. In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin α1. J Biol Response Mod 1983; 2: 139–49

    PubMed  CAS  Google Scholar 

  58. Dillman RO, Beauregard J, Royston I, et al. Phase II trial of thymosin fraction 5 and thymosin alpha 1. J Biol Response Mod 1987; 6: 263–7

    PubMed  CAS  Google Scholar 

  59. Bepler G. Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: a review. Cancer Invest 1994; 12: 491–6

    Article  PubMed  CAS  Google Scholar 

  60. Tomazic VJ, Sacasa CR, Loftus A, et al. Thymic factor-induced reduction of pulmonary metastases in mice with FSA-1 fibrosarcoma. Clin Exp Metastasis 1988; 6: 17–25

    Article  PubMed  CAS  Google Scholar 

  61. Mossman TR. T-lymphocyte subsets, cytokines, and effector functions. Ann NY Acad Sci 1992; 664: 89–92

    Article  Google Scholar 

  62. Romagnani S. Induction of TH1 and TH2 responses: a key role for the ‘natural’ immune response? Immunol Today 1992; 13: 379–81

    Article  PubMed  CAS  Google Scholar 

  63. Hadden JW. T-cell adjuvants. Int J Immunopharmacol 1994; 16: 703–10

    Article  PubMed  CAS  Google Scholar 

  64. Aiuti F, Sirianni MC, Fiorilli M, et al. A placebo-controlled trial of thymic hormone treatment of recurrent herpes simplex labialis infection in immunodeficient host: results after a 1-year follow-up. Clin Immunol Immunopathol 1984; 30: 11–8

    Article  PubMed  CAS  Google Scholar 

  65. Cappel R, deCuyper F, DeNeef K, et al. Effect of thymopentin on the mortality and immune response after an experimental herpes simplex infection in mice. Surv Immunol Res 1985; 4 Suppl. 1: 48–57

    Google Scholar 

  66. DeMauberge J, Haneke E, Djawari D, et al. Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study. Surv Immunol Res 1985; 4 Suppl. 1: 30–6

    Google Scholar 

  67. Abb J. Prevention and therapy of herpesvirus infections. Zentralbl Bakteriol Mikrobiol Hyg 1985; 180: 107–20

    CAS  Google Scholar 

  68. Tovo PA, Pugliese A, Palomba E, et al. Thymostimulin therapy in patients with measles meningoencephalitis. Thymus 1986; 8: 91–4

    PubMed  CAS  Google Scholar 

  69. Steel RW, Charlton RK. Immune modulators as antiviral agents. Clin Lab Med 1987; 7: 911–24

    Google Scholar 

  70. Chachoua A, Green MD, Valentine F, et al. Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndrome. Cancer Invest 1989; 7: 225–9

    Article  PubMed  CAS  Google Scholar 

  71. Hoofnagle JH. Chronic hepatitis B. New Engl J Med 1990; 323: 337–9

    Article  PubMed  CAS  Google Scholar 

  72. Eddleston ALWF. Overview of HBV pathogenesis. In: Hollinger FB, Lemon SM, Margolis HS, editors. Viral hepatitis and liver disease. B ltimore: Williams & Wilkins, 1991: 234–7

    Google Scholar 

  73. Mutchnick MG, Missirian A, Johnson AG. Lymphocyte cytotoxicity in human liver disease using rat hepatocyte monolayer cultures. Clin Immunol Immunopathol 1980; 16: 423–37

    Article  PubMed  CAS  Google Scholar 

  74. Mutchnick MG, Schaffner JA, Prieto JA, et al. Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis. Dig Dis Sci 1983; 28: 328–34

    Article  PubMed  CAS  Google Scholar 

  75. Dabrowski MP, Dabrowska-Bernstein BK, Brzosko WJ, et al. Immunotherapy of patients with chronic virus B hepatitis. I. Maturation of human T-lymphocytes under influence of calf thymic hormone. Clin Immunol Immunopathol 1980; 16: 297–307

    Article  PubMed  CAS  Google Scholar 

  76. Romeo F, Palmisano L, Arcoria D. Thymostimulin in the treatment of hepatitis B surface antigen-positive chronic active hepatitis. Arzneimittel Forschung 1987; 37: 450–6

    PubMed  CAS  Google Scholar 

  77. Zhang D-F, Chen GM, Fan C, et al. Suppressor cell function and thymopeptide therapy in viral hepatitis B. Chin Med J 1986; 99: 791–8

    PubMed  CAS  Google Scholar 

  78. Sheng S. Use of porcine thymic extract and thymic peptide in treatment of chronic hepatitis B and fulminant viral hepatitis. In: Goldstein AL, editor. Thymic hormones and lymphokines ’83. Washington DC: The George Washington University School of Medicine and Health Sciences, 1983: 94

    Google Scholar 

  79. Gerin JL, Korba BE, Cote PJ, et al. A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. In: Block T, et al., editors. Innovations in antiviral development and the detection of virus infection. New York: Plenum Press, 1992: 121–3

    Chapter  Google Scholar 

  80. Sherman KE, Jones CC, Goldstein AL, et al. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. Viral Immunol 1991; 4: 195–9

    Article  PubMed  CAS  Google Scholar 

  81. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991; 14: 409–15

    Article  PubMed  CAS  Google Scholar 

  82. Mutchnick MG, Jaurequi J, Shafritz D. Sustained response to thymosin therapy in patients with chronic hepatitis B [abstract]. Hepatology 1992; 16: 66A

    Google Scholar 

  83. Andreone P, Cursaro C, Gramenzi A, et al. A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B antigen antibody and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996; 24: 774–7

    PubMed  CAS  Google Scholar 

  84. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268–73

    PubMed  CAS  Google Scholar 

  85. Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology 1988; 8: 1651–4

    Article  PubMed  CAS  Google Scholar 

  86. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198–202

    Article  PubMed  CAS  Google Scholar 

  87. Fattovich G, Giustina G, Alberti A, et al. A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. J Hepatol 1994; 21: 361–6

    Article  PubMed  CAS  Google Scholar 

  88. Rasi G, Mutchnick MG, Di Virgilio D, et al. Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B. J Viral Hepat 1996; 3: 191–6

    Article  PubMed  CAS  Google Scholar 

  89. Farhat BA, Marinos G, Daniels HM, et al. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol 1995; 23: 21–7

    Article  PubMed  CAS  Google Scholar 

  90. Eichberg JW, Seef LB, Lawlor DL, et al. Effect of thymosin immunostimulation with and without corticosteroid immuno-suppression on chimpanzee hepatitis B carriers. J Med Virol 1987; 21: 25–37

    Article  PubMed  CAS  Google Scholar 

  91. Zav’yalova VP, Denesyuk AI, Zav’yalova GA. Theoretical analysis of conformation and active sites of interferons. Immunol Lett 1989; 22: 173–81

    Article  PubMed  Google Scholar 

  92. Zav’yalova VP, Navolotskaya EV, Abramov VM, et al. The octapeptide corresponding to the region of the highest homology between α-interferon and thymosin-α1 effectively competes with both cytokines for common high-affinity receptors on murine thymocytes. FEBS Lett 1991; 278: 187–9

    Article  Google Scholar 

  93. Moshier JA, Mutchnick MG, Dosescu J, et al. Thymosin-α1 but not interferon-α specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells. J Hepatol 1996; 25: 814–20

    Article  PubMed  CAS  Google Scholar 

  94. Taylor JM, Chao M, Hieh SY, et al. Structure and replication of hepatitis delta virus. In: Hollinger FB, et al., editors. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991: 460–3

    Google Scholar 

  95. Rizzetto M, Verme G, Gerin JI, et al. Hepatitis delta virus disease. In: Popper H, Schaffner E, editors. Progress in liver disease. New York: Grune & Stratton, 1986: 417–31

    Google Scholar 

  96. Zavaglia C, Bottelli R, Smedile A, et al. A pilot study of thymosin-alpha 1 therapy for chronic hepatitis B. J Clin Gastroenterol 1996; 23: 162–3

    Article  PubMed  CAS  Google Scholar 

  97. Rosina F, Conoscitore P, Giuliani A, et al. Treatment of chronic hepatitis D with the thymosin derivative THF gamma-2: results of a pilot study [abstract]. Hepatology 1994; 20: 309A

    Google Scholar 

  98. Rezakovic I, Zavaglia C, Bottelli R, et al. A pilot study of thymosin alpha 1 therapy in chronic active hepatitis C [abstract]. Hepatology 1993; 18: A252

    Article  Google Scholar 

  99. Andreone P, Cursaro C, Gramenzi A, et al. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver 1996; 16: 207–10

    PubMed  CAS  Google Scholar 

  100. Sherman KE, Sjogren MH, Creager RL, et al. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998; 27: 1128–35

    Article  PubMed  CAS  Google Scholar 

  101. Rasi G, Di Virgilio D, Mutchnick MG, et al. Combination thymosin α 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 1996; 39: 679–83

    Article  PubMed  CAS  Google Scholar 

  102. Camps J, Cordoba J, Esteban JI. Pathophysiology of chronic hepatitis C. In: Miguet JP, Dhumeaux D, editors. Progress in hepatology ’93. Paris: John Libbey Eurotext, 1993: 63–8

    Google Scholar 

  103. Negro F, Pacchioni D, Shimizu Y, et al. Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology. Proc Natl Acad Sci USA 1992; 89: 2247–51

    Article  PubMed  CAS  Google Scholar 

  104. Botarelli P, Brunetto MR, Minutello MA, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104: 580–7

    PubMed  CAS  Google Scholar 

  105. Gonzales-Peralta RP, Davis GL, Lau JYN. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994; 21: 255–9

    Article  Google Scholar 

  106. Zeldis JB, Jensen P. Hepatitis C virus pathogenicity: the corner pieces of the jigsaw puzzle are found. Gastroenterology 1994; 106: 1118–20

    PubMed  CAS  Google Scholar 

  107. Clerici M, Shearer GM. A TH1–TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107–11

    Article  PubMed  CAS  Google Scholar 

  108. Hersh EM, Reuben JM, Rios A, et al. Elevated serum thymosin alpha 1 levels associated with evidence of immune dysregulation in male homosexuals with a history of infectious diseases or Kaposi’s sarcoma. N Engl J Med 1983; 308: 45–6

    PubMed  CAS  Google Scholar 

  109. Haynes BF, Robert-Guroff M, Metzgar RS, et al. Monoclonal antibody against human T cell leukemia virus p19 defines a human thymic epithelial antigen acquired during ontogeny. J Exp Med 1983; 157: 907–20

    Article  PubMed  CAS  Google Scholar 

  110. Sarin PS, Sun DK, Thornton AH, et al. Neutralization of HTLV/LAV replication by antiserum to thymosin α1. Science 1986; 232: 1135–7

    Article  PubMed  CAS  Google Scholar 

  111. Chen SJ, Ko HS. Serum thymosin-alpha: lack of association between elevated levels and HIV infection. Clin Exp Immunol 1987; 70: 263–7

    PubMed  CAS  Google Scholar 

  112. Lotze MT. Treatment of immunologic disorders in patients with AIDS. In: De Vita VT, Hellman S, Rosenberg DA, editors. AIDS. New York: Lippincott, 1985: 235–64

    Google Scholar 

  113. Schulof RS, Simon GL, Sztein MB, et al. Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects. J Biol Response Mod 1986; 5: 429–43

    PubMed  CAS  Google Scholar 

  114. Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infection. Int J Clin Lab Res 1994; 24: 23–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, University of Bologna, Bologna, Italy

    Annagiulia Gramenzi, Carmela Cursaro,  Pietro Andreone & Mauro Bernardi

  2. Dipartimento di Medicina Interna,Cardioangiologia ed Epatologia, Policlinico S. Orsola, Via Massarenti 9, 40138, Bologna, Italy

    Pietro Andreone

Authors
  1. Annagiulia Gramenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmela Cursaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pietro Andreone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mauro Bernardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gramenzi, A., Cursaro, C., Andreone, P. et al. Thymalfasin. BioDrugs 9, 477–486 (1998). https://doi.org/10.2165/00063030-199809060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199809060-00005

Keywords

Search

Navigation